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S U M M A R Y
Objective: A meta-analysis was performed to compare mold-active triazoles or lipid amphotericin B plus
an echinocandin to non-echinocandin monotherapy for acute invasive aspergillosis (IA).
Methods: We searched PubMed, EMBASE, and other databases through May 2013 unrestricted by
language. We included observational and experimental studies wherein patients with proven or
probable IA by EORTC/MSG criteria underwent our comparative intervention. PRISMA and MOOSE
guidelines were followed and quality was assessed using the Jadad and Newcastle–Ottawa criteria.
Meta-regression with ﬁxed and random effects and sensitivity analyses were performed. The primary
study outcome measure was 12-week overall mortality. The secondary outcome assessed was complete
and partial response.
Results: Only observational studies of primary 12-week survival showed heterogeneity (I2 = 48.96%,
p = 0.05). For salvage IA therapy, ﬁxed effects models demonstrated improved 12-week survival (Peto
odds ratio (OR) 1.80, 95% conﬁdence interval (CI) 1.08–3.01) and success (Peto OR 2.17, 95% CI 1.21–3.91)
of combination therapy. Signiﬁcance remained after applying random effects as a sensitivity analysis
(12-week survival: Peto OR 1.90, 95% CI 1.04–3.46, and unchanged value for success). Restriction to high
quality studies and including echinocandins as the comparator for refractory IA revealed an adjusted OR
of 1.72 (95% CI 0.96–3.09; p = 0.07) for global success, while the survival endpoint remained unaltered.
Conclusions: Combination antifungals for IA demonstrate improved outcomes over monotherapy in the
salvage setting. Clinicians should consider this approach in certain situations.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Aspergillus species are ubiquitous fungi that can be inhaled and
develop into angioinvasive forms. The results of a study using data
from the Prospective Antifungal Therapy Alliance (PATH Alliance)
registry reported in 2012, showed the most common species§ Systematic Review Registration: http://www.crd.york.ac.uk/prospero/;
CRD42013004006.
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creativecommons.org/licenses/by-nc-nd/3.0/).causing invasive disease in decreasing frequency to be A. fumigatus,
A. ﬂavus, A. niger, A. terreus, and A. versicolor.1 Acute invasive
aspergillosis (IA) leads to high morbidity and mortality in the
immunocompromised host. For instance, data from the Transplant
Associated Infections Surveillance Network (TRANSNET) revealed
1-year survival from IA of 59% among solid organ transplant (SOT)
recipients and 25.4% among hematopoietic stem cell transplant
(HSCT) recipients, from 2001 to 2006.2,3 Despite improved care, IA-
associated hospitalization costs remain exorbitant. According to
data from the Healthcare Utilization Project (HCUP), the average
length of hospitalization due to IA in 1996 was 17.3  0.6 days,
corresponding to a cost of $62 426  $4977; this dropped in 2004 only
to 16.4  0.5 days with a reduction in cost to $41 891  $1842 Diseases. This is an open access article under the CC BY-NC-ND license (http://
A.A. Panackal et al. / International Journal of Infectious Diseases 28 (2014) 80–94 81(p = 0.09), which is still high.4,5 While sinopulmonary involvement is
most common, dissemination to the central nervous system,
gastrointestinal tract, skin, or contiguously may occur amongst the
severely immunosuppressed.
Effective therapeutic options are limited once infection is
established, relying on the host’s immune status to improve
outcomes. Historically, amphotericin B deoxycholate (AmB-d) – a
polyene that forms pores in the fungal ergosterol-laden cell
membrane – was deemed the ‘gold standard’ for treating IA, but
dose-related nephrotoxicity limited its widespread use.6 To lessen
the nephrotoxicity, lipid formulations were developed: liposomal
amphotericin B (L-AmB), amphotericin B lipid complex (ABLC), and
amphotericin B colloid dispersion (ABCD). However, infusion-
related toxicity was not eliminated by such modiﬁcations and
renal toxicity was found to persist at higher cumulative doses.
In May 2002, voriconazole – a triazole with high oral
bioavailability that inhibits a step in fungal cell membrane
ergosterol biosynthesis by blocking 14a-demethylase – received
approval for the primary therapy of IA as a consequence of the
clinical trial by Herbrecht et al.7 Voriconazole was found to be
superior to AmB-d, given its 52.8% vs. 31.6% 12-week global
response rate and 22% reduction in overall mortality (p = 0.02).7 In
a subsequent analysis, Patterson et al. found that fewer patients
receiving voriconazole switched to other antifungals due to disease
progression or intolerance than patients in the AmB-d arm (24% vs.
70%, p < 0.001), and, despite the switch, success at 12 weeks was
less common in the latter than in the former group (32% vs. 55%,
p < 0.001).8
Since IA treatment responses were found to remain poor in
certain populations (e.g., allogeneic HSCT) and in cases of
extrapulmonary involvement, with a positive response rate of
32–42%, alternative strategies were considered. In 2001, an
echinocandin – caspofungin – was approved as salvage therapy
for IA; the favorable response rate was 45–56%, with better
outcomes among those receiving it due to drug intolerance rather
than disease progression.9,10 A similar successful response rate but
lower 12-week survival (50%) was obtained when caspofungin was
used as primary therapy.11 Of particular interest is the unique
target of this class – b-1,3-glucan synthase, an enzyme that makes
an important component of some fungal cell walls.
Subsequently, several investigators noted further improve-
ments in outcome based upon in vitro and animal studies that
demonstrated synergistic or additive effects when combining a
mold-active triazole (itraconazole, voriconazole, or posaconazole)
or an amphotericin B with an echinocandin (caspofungin,
micafungin, or anidulafungin).12,13 These translational studies
led practitioners to use such combination therapy routinely, with
the hope of improving IA outcomes.
However, few human observational studies and small-scale
clinical trials have been published to support this practice. In fact,
logistical issues made recent completion of a randomized
controlled trial to investigate this approach for primary IA
challenging.14,15 Since investigators have found comparable 12-
week survival for voriconazole (70.8%) and lipid amphotericin B
(e.g., 72% using L-AmB 3 mg/kg) and comparable response rates
(50.8% compared to 50%, respectively) in the treatment of IA
among HSCT, SOT, and hematological malignancy patients when
used as primary therapy for IA, and because these classes have
largely similar salvage efﬁcacy, it is cogent to combine these to
minimize heterogeneity.7,16–18 Indeed, in a retrospective non-
comparative salvage study, Maertens et al. found no signiﬁcant
difference in the favorable response rate at 84 days when
caspofungin was combined with either an amphotericin B or
triazole.19 We therefore conducted a systematic review and meta-
analysis of studies that evaluated the efﬁcacy of combining mold-
active triazoles or a lipid amphotericin B product with anechinocandin compared to non-echinocandin monotherapy in
order to determine the optimum treatment strategy for IA.
2. Methods
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) and Meta-analysis Of Observational
Studies in Epidemiology (MOOSE) guidelines were followed in
describing our ﬁndings and standard methodology.20–22
2.1. Eligibility criteria
2.1.1. Inclusion criteria
Inclusion criteria encompassed any experimental or observa-
tional study in which mold-active triazoles or a lipid amphotericin
B product was used in combination with an echinocandin for
primary and/or salvage treatment of IA. Studies that investigated
sequential mono or dual therapies in a comparative manner were
permitted, given the prolonged antifungal drug half-life in the
setting of hepatic and/or renal failure that is prevalent in the
affected population. Salvage therapy was deﬁned as the receipt of
antifungal(s) due to prior antifungal intolerance (e.g., toxicity) or
refractory disease (e.g., clinical or microbiological progression). In
some studies, ‘other licensed antifungal therapies’ (OLAT) was used
as an aggregate term to encompass a mixture of such triazoles and
amphotericin B products. To enhance uniformity, we selected
studies on immunocompromised human cases that compared this
combined intervention to ‘monotherapy’ – a single antifungal drug
with similar IA survival rates (i.e., mold-active triazoles or a lipid
amphotericin B product in the primary and salvage settings) – to
permit analysis of our pooled study population. Furthermore, only
proven and probable IA cases were included, in accordance with
the original and revised European Organization for the Research
and Treatment of Cancer/Mycoses Study Group (EORTC/MSG)
guideline deﬁnitions.23,24 Studies needed to enable calculation of
12-week survival as our primary endpoint. Although most deaths
attributable to IA occur within 6 weeks after therapy, we found a
lack of consistency across studies in measuring this as an outcome
and so we chose 12-week survival as our major endpoint.25 The
secondary endpoint was composite clinical, microbiological, and
radiographic success (‘complete’ or ‘partial’ response) ascertained
at the end of treatment (EOT), according to previously published
deﬁnitions.26 To minimize publication bias, we included studies in
languages other than English.
2.1.2. Exclusion criteria
Exclusion criteria encompassed any case reports, case series,
reviews, guidelines, and non-human studies that dealt with our
research question. Any study that failed to have a comparator, did
not include the desired combination, or did not include data to
derive an effect measure of our endpoint was removed. In cases
where multiple studies included the same study subjects, only one
study was selected to avoid duplication.
2.2. Literature search
We conducted a systematic search of MEDLINE via PubMed (http:
//www.ncbi.nlm.nih.gov/PubMed), EMBASE (http://www.embase.
com), BIOSIS/Web of Knowledge (http://apps.webofknowledge.com.
ezproxy.nihlibrary.nih.gov/WOS_GeneralSearch_input.do?product=
WOS&search_mode=GeneralSearch&SID=4CMPf38K95Aj2alO2bo&
preferencesSaved=), the Cochrane Controlled Trials Register (http://
www.cochrane.org/cochrane/hbook.htm), the National Institutes of
Health (http://www.clinicaltrials.gov), and a meta-register of
controlled trials (http://www.controlled-trials.com) using the fol-
lowing search terms: antifungal, combination, and/or aspergillosis.
A.A. Panackal et al. / International Journal of Infectious Diseases 28 (2014) 80–9482These medical subject headings were deemed most expansive, but
were cross-checked with more speciﬁc terms such as aspergillosis,
echinocandin, triazole, or amphotericin B. Unpublished studies were
discovered using the British Library Index to Conference Proceedings
(http://www.bl.uk) and other sources (e.g., Google Scholar and
national and international meetings/abstracts).
2.3. Data extraction
Using a developed abstraction template, two investigators (AP
and EP) independently extracted data from studies meeting our
eligibility criteria. These investigators were blinded to the authors’
afﬁliated institutions, funding sources, and acknowledgments to
minimize ascertainment bias. Any discrepancies were resolved via
referencing the original source and group discussions. Piloting and
revision of the instrument was done as needed. We acquired the
following information: journal article citation, study type, mean age
of participants, sex ratio, source population (e.g., HSCT), predomi-
nant IA treatment indication (primary or salvage – the latter deﬁned   
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Data quality assessment with respect to the risk of bias was
performed among experimental studies using allocation methodol-
ogy, therapy concealment determination, outcome ascertainment
(reliability and validity), and attrition based on the Jadad method.27
Similar component sources of bias were determined for observa-
tional studies using the Newcastle–Ottawa scale.28
2.4. Data analysis
We stratiﬁed by therapeutic indication (primary vs. salvage)
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of combination antifungal therapy for the treatment of acute invasive aspergillosis.
Table 1
Observational and experimental studies of combination antifungal therapy compared with monotherapy for the treatment of invasive aspergillosis, meeting the inclusion criteria
Citation Type of
study
Study
location
Study
population
Predominant
indication
Combination
treatment
regimen
Combination
treatment duration
(median [range]
or Mean  SD
days, or
approximation)
Monotherapy
treatment
regimen
Monotherapy
treatment duration
(median [range] or
Mean  SD days, or
approximation)
Follow-up Age (median
[range] or
Mean 
SD years)
Male to
female
ratio
Munoz
et al.34
Retrospective
cohort
Boston, MA Hematological
malignancy
Primary Voriconazole +
caspofungin
N/A Voriconazole 14 >100 days NR NR
Steinbach
et al.35
Retrospective
cohort
USA
(multicenter)
HSCT, SOT,
hematological
malignancy
Primary OLAT + caspofungin 7 Voriconazole 14–28 12 weeks NR 2.1
Marr
et al.36
Retrospective
cohort
Seattle, WA HSCT Salvage Voriconazole +
caspofungin
68 [3–248] Voriconazole 33 [2–205] 3 months 47 [17–66] 0.62
Trullas
et al.37
Retrospective
cohort
Spain HSCT, SOT Primary AmB-d +
caspofungin
NR L-AmB or ABLC NR NR 51.714.1 1.81
Dı´az
Pedroche
et al.38
Retrospective
cohort
Spain SOT,
hematological
malignancy
Salvage Voriconazole +
caspofungin
NR Voriconazole NR 30 days 51.5 [4.5–75.5] 1.29
Singh
et al.39
Prospective
cohort
International
(multicenter)
SOT Primary Voriconazole +
caspofungin
NR L-AmB <90 90 days 50 [19–68] mono: 0.9;
combo: 2.1
Caillot
et al.48
Clinical trial France HSCT,
hematological
malignancy
Primary L-AmB +
caspofungin
18 [10–35] L-AmB
(10 mg/kg/day)
17 [4–24] 12 weeks 53.6 [16–75] 2.33
Waala
et al.40
Retrospective
cohort
Seattle, WA HSCT,
hematological
malignancy
Primary Voriconazole +
echinocandin
16.210 Voriconazole 28.128.2 3 months NR 0.8
Pagano
et al.41
Prospective
cohort
Italy
(multicenter)
AML Primary L-AmB or
voriconazole or
posaconazole +
caspofungin
20 [2–90] L-AmB or voriconazole
or posaconazole
20 [2–90] 120 days 57 [14–79] 1.8
Mihu
et al.42
Retrospective
cohort
Houston, TX Hematological
malignancy
Salvage L-AmB +
echinocandin
14 [2–112] L-AmB 8 [1–170] 12 weeks 50 [9–79] 1.6
Schwartz
et al.43
Retrospective
cohort
International
(multicenter)
HSCT, SOT,
hematological
malignancy
Salvage Voriconazole +
caspofungin
NR Voriconazole 48 [1–1128] 12 months 44 [0.75–81] 1.35
Lortholary
et al.44
Prospective
cohort
France HSCT, SOT,
hematological
malignancy
Primary Voriconazole +
OLAT
NR Voriconazole NR 12 weeks 56 [18–84] 1.64
Jacobs
et al.45
Prospective
cohort
Belgium
(multicenter)
HSCT, SOT,
hematological
malignancy
Primary Voriconazole +
OLAT
49.5 [1–183] Voriconazole 32 [1–183] 183 days 55.6 [14–85] 1.46
Marr
et al.14
Clinical trial International
(multicenter)
HSCT,
hematological
malignancy
Primary Voriconazole +
anidulafungin
14–28 Voriconazole 42 12 weeks 52 [18–83] 1.25
Racil
et al.46
Retrospective
cohort
Czech Republic
(multicenter)
HSCT,
hematological
malignancy
Primary +
salvage
Voriconazole +
caspofungin
19 [5–159] Voriconazole or
L-AmB
15 [5–139] 12 months 56 [3–77] 1.44
Baddley
et al.47
Retrospective
cohort
USA
(multicenter)
HSCT, SOT Primary Voriconazole or L-
AmB + caspofungin
Mean 115 Voriconazole or
L-AmB
Mean 115 12 weeks 4914.7 1.55
Citation Organ involvement Number in combina-
tion group
Number inmonother-
apy group
Data quality assessment points:
Experimental studies* (max. 5 points)
Data quality assessment points:
Observational studiesz (max. 9 points)
Pulmonary Extrapulmonary Primary Salvage Primary Salvage Randomized Concealment Attrition Selection Comparability Outcome
Munoz et al.34 NR NR 10 N/A 24 N/A N/A N/A N/A 2 1 0
Steinbach et al.35 74 9 17 N/A 34 N/A N/A N/A N/A 4 1 2
Marr et al.36 40 7 N/A 16 N/A 31 N/A N/A N/A 4 2 3
Trullas et al.37 25 6 8 N/A 13 N/A N/A N/A N/A 2 0 0
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the Mantel–Haenszel test (data not shown); this was accompanied
by a 95% conﬁdence interval (CI). More conservative random effects
conﬁdence intervals were also displayed when the test of
heterogeneity was signiﬁcant and the number of studies in the
group was greater than eight. These were based on DerSimonian and
Laird weights in conjunction with a permutation method using a t
reference distribution.30,31 Residual heterogeneity (t2) was calcu-
lated and represented pictorially using Galbraith plots (Z-score vs.
precision). To control for potential confounders, we then determined
a quantitative summary estimate, using multivariate meta-regres-
sion by study quality components. A ‘high’ score was conferred
among clinical trials for each Jadad criterion 1 and among
observational studies for each Newcastle–Ottawa component:
selection >2 (on a 0–4 scale), comparability >1 (on a 0–2 scale),
and outcome >1 (on a 0–3 scale). Inappropriate control of such
parameters will inﬂuence the magnitude and directionality of the
effect estimate, which may create spurious results.32
A sensitivity analysis, including studies in which an echino-
candin was the monotherapy comparator, was also performed.
Moreover, since random effects analysis permits investigating the
effect of changing the weights of the different studies, with larger
studies being given less weight, this method was presented as an
additional sensitivity analysis in certain instances.31 Publication
bias was depicted using funnel plots of the inverse standard error –
a marker of study sizes – against the effect measure of each study
and was quantiﬁed by the Egger regression test for plot
asymmetry.33 All analyses were performed initially using R
version i386 3.0.1 (2013-05-16; The R Foundation for Statistical
Computing: http://www.r-project.org/) with package ‘metafor’ (by
AP) and then subsequently conﬁrmed and presented in S-Plus
(Tibco Software Inc.) (by MP).
3. Results
Figure 1 depicts the selection process for studies pertaining to
combination versus monotherapy of IA. A total of 4331 citations
were identiﬁed via our medical subject heading search and the
majority (60%) were removed after excluding duplicates and
focusing on our inclusion criteria. Of the remaining 90 screened,
55 full-text articles were assessed for eligibility. Thirty-three were
reviewed in further detail, but nine were excluded from the
quantitative meta-analysis, as these did not provide sufﬁcient
information to produce an outcome estimate. Of the remaining
24 articles, 16 (k = 16) were included in the initial analysis
(Table 1)14,15,34–48 and eight (k = 8) were added (echinocandin
comparator) in the sensitivity analysis (Table 2A).49–56 Table 2B
lists current or withdrawn clinical trials on the topic.
In the initial analysis, the total number of subjects in the
combination therapy arm was 629 (502 primary, 127 salvage) and
that in the monotherapy arm was 1204 (973 primary, 231 salvage).
Regarding sites of infection, 1644 were pulmonary (1309 primary,
170 salvage, and 165 both) and 326 were extrapulmonary
(159 primary, 156 salvage, and 11 both). The age and male to
female ratio distribution was similar among the combination and
monotherapy groups (age: median (interquartile range) 51.7
(50.0–55.6) years and 1.50 (1.32–1.52) years, respectively). The
source population comprised HSCT patients (11 studies), SOT
patients (eight studies), and patients with a hematological
malignancy (12 studies). Similar measures of duration of therapy
for combination and monotherapy were not easily estimable as
there was variability in reporting and, when reported, the duration
spanned a wide range.
Figure 2 illustrates the summary effect measure across studies
by primary or salvage therapeutic indication for IA. Observational
studies of primary 12-week survival demonstrated heterogeneity
Table 2
Studies in which an echinocandin was used as a comparator to combination therapy with an echinocandin and a mold-active triazole or lipid amphotericin B product for the treatment of invasive aspergillosis. See text and Figure 2e
for the sensitivity analysis
(A)
Citation Type of
study
Study
location
Study
population
Predominant
indication
Combination
treatment
regimen
Combination
treatment
duration
(median
[range] or Mean
 SD days, or
approximation)
Monotherapy
treatment
regimen
Monotherapy
treatment duration
(median [range]
or Mean  SD days,
or approximation)
Follow-up Age
(median
[range] or
Mean  SD
years)
Male to
female
ratio
Denning
et al.55
Clinical trial International
(multicenter)
HSCT, SOT,
hematological
malignancy, others
Primary + salvage Micafungin + OLAT 35 [7–284] Micafungin <90 6 weeks after Rx 36 [0.2–84] 1.73
Izumikawa
et al.49
Retrospective
cohort
Japan non-HSCT, non-
hematological
malignancy
Primary OLAT + micafungin 59.2 [29–96] Micafungin 59.2 [29–96] EOT 61.9 [20–83] 3.5
Kontoyiannis
et al.50
Prospective
cohort
International
(multicenter)
HSCT Primary + salvage OLAT + micafungin NR Micafungin NR 90 days NR NR
Lichtenstern
et al.51
Retrospective
cohort
Multinational
(Germany and
other European
countries)
SOT Primary OLAT + caspofungin 56 [22–228] Caspofungin 59 [9–398] 7 days after EOT 56 1.92
Maertens
et al.52
Prospective
cohort
International
(multicenter)
HSCT,
hematological
malignancy
Primary + salvage OLAT + caspofungin NR Caspofungin NR 7 days after EOT 50.416.09 1.64
Winkler
et al.53
Retrospective
cohort
International
(multicenter)
SOT Primary OLAT + caspofungin NR Caspofungin NR 7 days after EOT NR NR
Egerer
et al.54
Retrospective
cohort
International
(multicenter)
HSCT,
hematological
malignancy, other
Primary + salvage OLAT + caspofungin NR Caspofungin 13.7 [5–38] 7 days after EOT 57 [17–75] 1.33
Jarque
et al.56
Clinical trial Spain Hematological
malignancy
Salvage Voriconazole or L-
AmB + caspofungin
19 [2–52] Caspofungin 19 [2–52] 28 days 52 [23–78] 1.5
(B)
Citation Pulmonary Extrapulmonary Primary combo Salvage combo Primary mono Salvage mono Randomized* Concealment* Attrition* Selectionz Comparabilityz Outcomez
Denning et al.55 61 19 17 173 12 22 0 1 1 N/A N/A N/A
Izumikawa et al.49 9 0 5 N/A 4 N/A N/A N/A N/A 2 1 1
Kontoyiannis et al.50 81 17 7 83 2 4 N/A N/A N/A 4 1 2
Lichtenstern et al.51 NR NR 4 N/A 4 N/A N/A N/A N/A 4 1 2
Maertens et al.52 87 16 5 11 15 70 N/A N/A N/A 4 2 2
Winkler et al.53 NR NR 10 N/A 9 N/A N/A N/A N/A 3 1 2
Egerer et al.54 NR NR 1 5 10 26 N/A N/A N/A 4 1 1
Jarque et al.56 34 0 N/A 20 N/A 14 0 0 1 N/A N/A N/A
*Jadad quality assessment scale; zNewcastle-Ottawa quality assessment scale; HSCT=hematopoietic stem cell transplant; SOT= solid organ transplant; EOT= end of treatment; N/A=not applicable; NR=not reported;
OLAT=other licensed antifungal therapy; Antifungal drug doses were as follows unless otherwise indicated: itraconazole 200mg IV or po TID; voriconazole 6mg/kg IV or po q12h1 day followed by 4mg/kg IV q12h;
posaconazole 200mg po TID; liposomal amphotericin B (L-AmB) 3–5mg/kg IV qd; amphotericin B lipid complex (ABLC) 5mg/kg IV qd; amphotericin B colloid dispersion (ABCD) 3–4mg/kg IV qd; amphotericin B deoxycholate
(AmB-d) 0.7mg/kg IV qd; caspofungin 70mg IV1d then 50mg IV qd; Micafungin 100mg IV qd; Anidulafungin 200mg IV1 then 100mg IV qd; Dosages are as mentioned unless otherwise stated in table text.
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A.A. Panackal et al. / International Journal of Infectious Diseases 28 (2014) 80–9486(t2 = 0.20  0.22; I2 = 49.0%; p = 0.05). This was conﬁrmed visually by
the Galbraith plot (Figure 2a, right); under homogeneity, only about
one in 20 trials should lie on or outside the two dotted lines. The ﬁxed
effects model produced a Peto OR of 1.36 (95% CI 1.02–1.80). The
random effects model, however, failed to attain statistical signiﬁ-
cance, yielding an OR of 1.25 (95% CI 0.74–2.09). Nonetheless, the two
clinical trials remained uniform (p = 0.26), with signiﬁcantly im-
proved survival with combination therapy compared to monotherapy
(Peto OR 1.66, 95% CI 1.02–2.68) (Figure 2a). The composite success of
primary therapy was relatively homogeneous across observational
(p = 0.13) and clinical trials (p = 0.20), as noted in the Galbraith plot,
but failed to attain statistical signiﬁcance (Figure 2b). For salvage IA
therapy, ﬁxed effects models were used (test of heterogeneity
p = 0.28 for 12-week survival and p = 0.76 for global success) and
conﬁrmed signiﬁcantly improved 12-week survival (Peto OR 1.80,
95% CI 1.08–3.01) (Figure 2c) and success (Peto OR 2.17, 95% CI 1.21–
3.91) (Figure 2d) of combination therapy compared to monotherapy
for IA. These effects remained signiﬁcant after applying a random
effects approach as a sensitivity analysis (12-week survival: Peto OR
1.90, 95% CI 1.04–3.46, and unchanged value for success).
Since echinocandins have comparable efﬁcacy to the newer
mold-active triazoles and lipid amphotericin B formulations for
refractory IA and are indicated for salvage IA monotherapy, we
added the echinocandin comparator studies in this setting (k = 6;
Table 2A). Figure 2e illustrates that the aggregate effect measure
for success remained signiﬁcant – albeit less compared to Figure 2d
– in favor of combination therapy (Peto OR 1.78, 95% CI 1.08–2.94)
from observational studies. However, the combined clinical trials
for salvage IA therapy, which were only available with echino-
candins as a comparator, did not yield a signiﬁcant overall
composite success (Peto OR 0.98, 95% CI 0.44–2.21). Moreover,
inclusion of this drug class, which has known lower efﬁcacy
compared to the newer triazoles and liposomal amphotericin B for
primary IA (k = 3), was inﬂuential on the overall composite success
of primary observational studies in an unexpected direction (i.e.,
no longer signiﬁcant, with ﬁxed effects Peto OR 1.29, 95% CI 0.87–
1.92 compared to Figure 2a). Survival was not systematically
assessed as an endpoint in these studies.
Funnel plots showed a predominant lack of publication bias
except for studies that included primary composite success as an
endpoint (Egger’s regression test under a mixed effects model for
funnel plot asymmetry, p = 0.03), given the breadth of our
literature search and inclusion of non-English language studies
(Figure 3). However, with so few studies by indication and
outcome, it is difﬁcult to draw ﬁrm conclusions.
Since we found a signiﬁcant effect of combination therapy
among salvage observational studies, which can be prone to
selection bias, and noted no such effect among the clinical trials,
which are designed to avoid such systematic errors in allocation,
we performed meta-regression on ‘high quality’ studies according
to the Newcastle–Ottawa components. The adjusted effect
measure for salvage 12-week survival remained unchanged (OR
1.80, 95% CI 1.08–3.01, p = 0.02), but the composite success
outcome became marginal (OR 1.72, 95% CI 0.96–3.09, p = 0.07).
The clinical trials failed to meet ‘high quality’ marks in the salvage
setting (Jadad score <3).
4. Discussion
Our results indicate that there is meta-evidence to support that
dual antifungal therapy affords signiﬁcantly improved 12-week
survival and composite success over monotherapy when given as
salvage therapy for IA. To control for confounding by indication in
the absence of a propensity score-matched analysis, we stratiﬁed
by primary and salvage therapy, ﬁnding that there was an 80%
increased odds of 12-week survival among those who received
Figure 2. Forest (left column) and Galbraith (right column) plots of studies containing data of combination antifungal therapy versus monotherapy by therapeutic indication
and primary and secondary outcomes (as deﬁned in the text). (a) Primary survival. (b) Primary clinical response. (c) Salvage survival. (d) Salvage clinical response. The
composite effect measure is expressed as the Peto odds ratio. A ﬁxed effects model was ﬁtted for all analyses. If heterogeneity was present via the I2 test and Galbraith plots (x-
axis = inverse standard error or precision; y-axis = Z-score; slope is the model point estimate) and the number of studies (k) > 8, a random effects model using the
DerSimonian–Laird estimator and an approximate t-test for conﬁdence intervals are also reported (see text). (e) When studies that included echinocandins as the
monotherapy comparator for salvage were included, since this drug class has similar efﬁcacy for refractory invasive aspergillosis as the other single drug classes, combination
therapy remained of signiﬁcant beneﬁt over monotherapy among observational studies; the success endpoint is only listed as survival and was not uniformly assessed in
these studies. RCT = clinical trials and not necessarily the method of allocation.
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A.A. Panackal et al. / International Journal of Infectious Diseases 28 (2014) 80–94 89combination therapy compared to those who received single-drug
therapy as salvage, and this effect remained when restricted to
high-quality observational studies. The global success dropped 39–
45% (all vs. high quality studies) after adding similar studies in
which echinocandins were the comparator, but remained signiﬁ-
cant. Moreover, although salvage therapy clinical trials found no
beneﬁt, their quality was poor.Our results also demonstrated that the meta-evidence to
support the routine use of combination antifungal therapy for
initial target IA treatment is less pronounced. While our ﬁxed
effects model showed a beneﬁt of combination therapy for 12-
week survival in both study designs, the heterogeneity among the
observational studies negated this when random effects were
applied. Of note, when we restricted observational studies on
Fig. 2. (Continued ).
A.A. Panackal et al. / International Journal of Infectious Diseases 28 (2014) 80–9490primary therapy to high-quality studies, the group became
relatively homogeneous (p = 0.16) and the adjusted 12-week
survival effect measure became signiﬁcant (OR 1.50, 95% CI
1.10–2.06, p = 0.01). Overall success was not found to be signiﬁcant
in either study design. This is in line with the recently completed
clinical trial by Marr et al., which showed a marginal 12-week
survival effect of combination therapy with voriconazole and
anidulafungin compared with voriconazole alone (p = 0.08, 95% CI
21.4 to 1.09) for primary IA treatment. Of note, global success
favored monotherapy in this trial (p = 0.08, 95% CI 21.6 to
1.15).14,15 Incidentally, when we compared primary to salvage
studies, we found insufﬁcient evidence to conclude that any
beneﬁt of combination therapy is differential by indication
(p = 0.34 and 0.21 for our survival and success endpoints,
respectively). This corroborates the ﬁndings of Kontoyiannis
et al., who demonstrated that L-AmB combined with caspofungin
resulted in no signiﬁcant difference in composite response amongthose who received it for primary vs. refractory or intolerant to
treatment IA (53% vs. 35%, p = 0.36).57
Combination modalities may be useful when the IA species is
unknown. Also, if there are concerns for antifungal resistance,
combination therapy may expand the armamentarium available
until susceptibility testing is back. Thirdly, since voriconazole
requires at least 5 days for the achievement of steady-state when a
loading dose is not given and its metabolism can be highly
inﬂuenced by concomitant medications, overlapping a compli-
mentary antifungal may be prudent. Finally, the various ampho-
tericin B formulations, triazoles, and echinocandins exhibit
different tissue penetrations based on their pharmacodynamic
properties such that the choice of antifungal may depend upon the
major site of infection. However, we found no signiﬁcant difference
in site of infection among the salvage treatment group (p = 0.27),
whereas ‘pulmonary’ was the predominant location in the primary
indication group (p = 0.01). Unfortunately, efﬁcacy by site of
Figure 3. Funnel plots of observational and experimental studies comparing combination to monotherapy of invasive aspergillosis (as deﬁned in the text) for (A) primary, and
(B) refractory disease (i.e., salvage). These illustrate statistically signiﬁcant asymmetry around the null value only for primary composite success, suggesting the presence of
publication bias in which smaller studies with less weight and precision are more likely to be published only if a strong treatment effect is noted. No asymmetry was noted
when echinocandin as comparator studies were added (e.g., salvage RCT, not shown). RCT = clinical trials and not necessarily the method of allocation.
A.A. Panackal et al. / International Journal of Infectious Diseases 28 (2014) 80–94 91infection was not evaluable except in the salvage study by
Schwartz et al. on central nervous system IA (Table 1 and
Figure 2).43
Our study had several limitations. First, the beneﬁt of
combination modalities is highly dependent on the level of
immune reconstitution and changes in practice over time – factors
that could not be adequately accounted for by a test for trend in our
study, since we lacked individualized patient data that captured all
necessary parameters, despite much effort on our part to obtain
such data through collaboration. For instance, in several of our
included studies, patients whose death was expected soon afterdiagnosis due to their underlying co-morbidities were excluded.
Hence, our ﬁndings of efﬁcacy may have been diminished if such
patients were captured in the primary data, making our conclu-
sions only applicable to settings outside such scenarios. Indeed,
other potential confounders such as neutropenia, conditioning or
other immunosuppressive regimens, graft versus host disease, and
underlying disease were abstracted when possible. We found
consistent balance among intervention groups, inferring that the
non-differential distribution would only bias towards the null if
there were misclassiﬁcation. Secondly, sources of heterogeneity
that were limitations of this meta-analysis included the following:
Fig. 2. (Continued ).
A.A. Panackal et al. / International Journal of Infectious Diseases 28 (2014) 80–9492(1) speciﬁc drug combination (e.g., OLAT, though this was in the
primary indication studies and sensitivity analyses – not affecting
the main conclusions of our study); (2) high-risk source popula-
tions (e.g., HSCT, SOT, and hematological malignancy) with
variable response rates; (3) etiologic Aspergillus species that may
have diverse pathogenicity; (4) extent of organs involved
(pulmonary vs. extrapulmonary); and (5) variable duration of
therapy and ascertainment of response at the end of therapy or
follow-up. Regarding the latter, some studies determined the
response at EOT and/or the end of the study, which were not
always the same, making direct comparisons untenable. However,
while the inclusion of studies in which EOT occurred before the end
of the study may have diminished the composite success effect
measure, we still noted signiﬁcance among salvage studies.
Thirdly, the dose and duration of antifungal treatment, which
impact pharmacokinetics, were not consistently and uniformly
reported, thus this source of heterogeneity could not be examined.
Finally, groups in which patients received salvage therapy could do
so if their disease progressed or they developed toxicity to the
current regimen. Since all of the included salvage studies in which
the reason for salvage was indicated (7 of 10) comprised
predominantly the former group (179 (77.5%) of 231 in the
combination group and 157 (60.4%) of 260 in the monotherapy
group), but reported outcome collectively as ‘refractory or
intolerant to treat’, except for one,50 we reasoned that the
enhanced treatment effect of combination therapy in this setting
was magniﬁed, since the refractory sub-group was in general more
ill. Future studies should collect outcome data on these salvage
sub-groups if proportions change over time to minimize con-
founding (by ‘contraindication’ for drug interactions and adverse
events, for instance).
Hence, our ﬁndings should be interpreted with caution given
the inherent limitations of meta-analyses and should be applied
only in certain clinical scenarios, such as refractory IA in the setting
of host immune recovery. Indeed, time-varying covariates, such aschanges in conditioning regimens for HSCT that may ameliorate
host immune status, could make our conclusions based on past
studies yield uncertain applicability in the future (i.e., a cohort
effect).
To conclude, we systematically and quantitatively found the
use of either a triazole or lipid amphotericin B formulation in
combination with an echinocandin to be beneﬁcial in certain
salvage settings. Although the caveat of heterogeneity is inherent
with any meta-analysis, the difﬁculties in completing the clinical
trial by Marr et al. (for primary IA treatment comparing
modalities), makes the probability of a similar appropriately
powered and comparative, double-blinded, multicenter trial for
salvage therapy low, reinforcing the importance of our results.
Synergism works in refractory disease, perhaps by killing
heteroresistant sub-populations, or by killing more rapidly
through potentiation. Nonetheless, host immune reconstitution
is necessary to afford cure, regardless of modality. Future studies
should address this prospectively, correlating host immunological
markers and outcomes, particularly since IA outcomes have been
improving over time with similar antifungal regimens due to
medical advancements.
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